Before the availability of biological therapies, corticosteroids and narcotics were frequently used in patients with inflammatory bowel disease (IBD) because of a paucity of disease-modifying therapies.
The increased accessibility to effective biologicals for IBD over the last decade should be leading to less use of corticosteroids and narcotic medications.
Dr Jean-Frederic Colombel and colleagues examined trends in prescriptions of corticosteroids and narcotics to patients with IBD in the United States during the period 2003 to 2011.
Data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey were used to examine visits of patients with IBD.
The team explored trends in corticosteroid and narcotic prescriptions, and predictors of use were assessed using survey-weighted chi-square tests.
|Biological prescriptions increased from to 16% by 2011|
|Inflammatory Bowel Diseases|
From 2003 to 2011, a total of 1119 patients with IBD had visits recorded in the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey databases.
The team found that although biological prescriptions significantly increased from 3% in 2003 to 2005 to 16% in 2009 to 2011, there was no significant decrease in corticosteroid or narcotic prescriptions during this same time frame.
The researchers noted that patients with IBD were less likely to receive narcotics when seeing a medical specialist compared with primary care physicians or surgeons.
Dr Colombel's team concludes, "Despite the availability of more effective biological therapies, prescriptions for corticosteroids and narcotics did not decline in patients with IBD visiting U.S. ambulatory clinics and emergency departments from 2003 to 2011."